Latanoprost SR is under clinical development by Peregrine Ophthalmic and currently in Phase I for Unspecified Ophthalmological Disorders.

Gland Pharma, a generic injectable–focused pharmaceutical company, has received approval from the United States Food and Drug Administration (FDA) for latanoprost ophthalmic solution, 0.005% (2.5 mL ...

The rapid microbial reduction, along with the complete reduction of all microbial challenges with latanoprost ophthalmic solution with BAK, demonstrates that its antimicrobial activity exceeds ...

Latanoprost ophthalmic solution 0.005% with 0.02% BAK or travoprost 0.004% ophthalmic solution with sofZia were tested against the following bacteria and fungi: Staphylococcus aureus (ATCC 6538 ...